Research Article
BibTex RIS Cite

The correlation between clinical prognosis together with the treatment of chronic Hepatitis B infection and Serum CD 95 (FAS) and Nitric Oxide levels in children

Year 2023, Volume: 16 Issue: 3, 495 - 502, 18.12.2023

Aylin Kont Özhan Mehmet Yavuz Çoşkun

Abstract

Aim: Nitric oxide (NO) and CD 95 (FAS) are thought to play a role in inflammation and apoptosis in chronic hepatitis B infections. This study aimed to examine the serum NO and CD 95 levels of children with chronic hepatitis B infection in comparison with healthy children. Method: 69 patients between the ages of 1 and 18 who were diagnosed with chronic hepatitis B were included in the study. 32 patients (21 boys, 11 girls) with chronic inactive hepatitis B infection as group 1, 37 patients with chronic active hepatitis B infection (25 boys, 12 girls) as group 2 and 32 healthy children (18 boys, 14 girls) as control group were included. Serum NO and CD 95 levels were measured. Comparisons between patient and control groups were made. Results: The mean age was 10.1±3.1 years in group 1, 9.3±3.3 years in group 2 and 9.2±1.8 years in the control group (p>0.05). Serum NO and CD 95 levels showed significant differences between the patient group and the control group (72.2±36.9 vs. 38.5±17.3 mµ, p<0.001 and 36.5±11% vs. 29.1±8.1%, p<0.001, respectively). Serum NO and CD 95 levels of Group 1 were found to be higher than the control group (73.7±38.9 vs. 38.5±17.3 mµ, p<0.01 and 34.8±9.1% vs. 29.1±8.1%, p<0.05, respectively). Serum NO and CD 95 levels of Group 2 were found to be higher than the control group (71.0±35.5 vs. 38.5±17.3 mµ, p<0.01 and 38.1±12.4% vs. 29.1±8.1%, p<0.05, respectively). Serum NO and CD 95 levels did not show significant difference between Group 1 and Group 2 (p>0.05). Conclusion: Serum NO and CD 95 levels were found to increase in children with chronic inactive hepatitis B infection and in children with chronic active hepatitis B infection.

Keywords

Hepatitis B virus chronic hepatitis B infection apoptosis CD 95 (FAS) nitric oxide (NO)

References

  • The World Health Organization. Hepatitis B. https://www.who.int/news-room/fact-sheets/detail/hepatitis-B. Temmuz 2023’de basıldı. Temmuz 2023’de erişildi.
  • Stinco M, Rubino C, Trapani S, Indolfi G. Treatment of hepatitis B virüs infection in children and adolescents. World J Gastroenterol. 2021;27(36):6053-6063. doi:10.3748/wjg.v27.i36.6053.
  • Indolfi G, Easterbrook P, Dusheiko G, et al. Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol. Hepatol. 2019;4(6): 466–476. doi: 10.1016/S2468-1253(19)30042-1.
  • Türkiye Viral Hepatit Önleme ve Kontrol Programı 2018-2023. https://hsgm .saglik.gov.tr/depo/Yayinlarimiz/Programlar/Turkiye_Viral_Hepatit_Onleme_ve_Kontrol_Programi_2018-2023.pdf;2018.
  • McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985;151(4):599–603. doi: 10.1093/infdis/151.4.599.
  • Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol. 1980;68:251-306. doi: 10.1016/s0074-7696(08)62312-8.
  • Kiraz S, Ertenli I, Oztürk MA, et al. Increased soluble FAS suggest delayed apoptosis in Familial Mediterranean Fever complicated with amyloidozis. J Rheum. 2003;30(2):313-315.
  • Rudin CM, Thompson CB. Apoptosis and Disease: Regulation and Clinical relevance of Programmed Cell Death. Annu. Rev. Med. 1997;48:267-281. doi: 10.1146/annurev.med.48.1.267.
  • Hetts SW. To Die or Not To Die. Jama. 1998; 279(4): 300-307. doi: 10.1001/jama.279.4.300. PMID: 9450715.
  • Rust C, Gores GJ. Apoptosis and Liver disease. Am J Med. 2000;108(7):567-574. doi: 10.1016/s0002-9343(00)00370-3.
  • Andreoli TE. The Apopitotic Syndromes. Am J Med. 1999; 107(5): 488.doi: 10.1016/s0002-9343(99)00258-2.
  • Panossian A, Hambartsumyan M, Panosyan L, et al. Plasma nitric oxide level in Familial Mediterranean Fever and its modulations by Immuno-Guard. Nitric Oxide. 2003; 9(2): 103-110. doi: 10.1016/j.niox.2003.08.005.
  • Braderick A. Clinical manifestations and diagnosis of hepatitis B virüs infection in children and adolescant. UpToDate. Avaible from: http://www uptodate.com. Nisan 2023’de basıldı. Temmuz 2023’de erişildi.
  • Oksuz M, Akkiz H, Isiksal YF, et al. Expression of Fas antigen in liver tissue of patients with chronic hepatitis B and C. Eur J Gastroenterol Hepatol. 2004;16(3): 341-345. doi: 10.1097/00042737-200403000-00015.
  • Mochizuki K, Hayashi N, Hiramatsu N, et al. Fas Antigen Expression in Liver Tissues of Patients With Chronic Hepatitis B. J Hepatol. 1996;24(1):1-7. doi:10.1016/s0168-8278(96)80178-4.
  • Lapinski TW, Kowalczuk O, Prokopowicz D, Chyzewski L. Serum concentration of sFas and sFasL in healty HbsAg carriers, chronic viral hepatitis B and C patients. World J Gastroenterol. 2004;10(24):3650-3653. doi: 10.3748/wjg.v10.i24.3650.
  • Song le H, Binh VQ, Duy DN, et al. Variations in the serum concentrations of soluble Fas and soluble Fas ligand in Vietnamese patients infected with hepatitis B virus. J Med Virol. 2004;73(2):244-249. doi: 10.1002/jmv.20082.
  • Hamazaki K, Gochi A, Matsubara N, Mori M, Orita K. Expression of Fas antigen and Bcl-2 protein in hepatocelluler carsinoma. Acta Med. 1995;49(4):227-230. doi: 10.18926/AMO/30379.
  • Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J. 1994;298:249-258.
  • Guidotti LG, Guilhot S, Chisara FV. Interleukin-2 and alpha/beta interferon downregulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and independent pathways. J Virol.1994;68(3):1265-1270. doi:10.1128/JVI.68.3.1265-1270.1994.
  • Koulentaki M, Notas G, Petinaki E, et al. Nitric oxide and pro-inflammatory cytokines in acute hepatitis B. Eur J Intern Med.2004;15(1):35-38. doi: 10.1016/j.ejim.2003.11.004.
  • Wang K, Han LY, Lu Q, Wang B, Li XH, Wang HM. Nitric oxide and nitric oxide synthase in patients with chronic hepatitis B. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2005; 19(2): 142-145.
  • Liu RH, Jacop JR, Tennant BC, Hotchkiss JH. Nitrite and nitrosamine synthesis by hepatocytes isolated from normal woodchucks (Marmota monax) and woodchucks chronically infected with woodhuck hepatitis virus. Cancer Res. 1992;52(15):4139-4143.
  • Ersoy Y, Bayraktar M, Mızrak B, et al. The level of endothelin-1 and nitric oxide in patients with chronic viral hepatitis B and C and correlation with histopatological grading and staging. Hepatol Res. 2006; 34(2): 111-116. doi: 10.1016/j.hepres.2005.11.005
  • Amaro MJ, Bartolome J, Pardo M, Cotonat T, Lopez A, Carreno V. Decreased nitric oxide production in chronic viral hepatitis B and C. J Med Virol.1997;51(4):326-331. doi: 10.1002/(sici)1096-9071(199704)51:4<326::aid-jmv11>3.0.co;2-g.

Çocukluk çağı kronik Hepatit B hastalığının klinik seyir ve tedavisi ile Serum CD 95 (FAS) ve Nitrik Oksid düzeyleri arasındaki ilişkinin belirlenmesi

Year 2023, Volume: 16 Issue: 3, 495 - 502, 18.12.2023

Aylin Kont Özhan Mehmet Yavuz Çoşkun

Abstract

Amaç: Nitrik oksid (NO) ve CD 95’ in (FAS) kronik hepatit B enfeksiyonlarında inflamasyonda ve apoptozisde rol oynadığı düşünülmektedir. Bu çalışmada, kronik hepatit B enfeksiyonu olan çocukların serum NO ve CD 95 düzeylerinin sağlıklı çocuklarla karşılaştırmalı olarak incelenmesi amaçlandı. Yöntem: Kronik hepatit B tanısı ile izlenen 1-18 yaş arası 69 hasta çalışmaya dahil edildi. Kronik inaktif hepatit B enfeksiyonu olan 32 hasta (21 erkek, 11 kız) grup 1 olarak, kronik aktif hepatit B enfeksiyonu olan 37 hasta (25 erkek, 12 kız) grup 2 olarak ve 32 sağlıklı çocuk (18 erkek, 14 kız) kontrol grubu olarak sınıflandırıldı. Serum NO ve CD 95 düzeyleri ölçüldü. Hasta ve kontrol grubu karşılaştırmaları yapıldı. Bulgular: Ortalama yaş grup 1’ de 10.1±3.1 yıl, grup 2’ de 9.3±3.3 yıl ve kontrol grubunda 9.2±1.8 yıl bulundu (p>0.05). Hasta grubu ve kontrol grubu arasında serum NO ve CD 95 düzeyleri anlamlı farklılık gösterdi (sırasıyla 72.2±36.9’a karşılık 38.5±17.3 mµ, p<0.001 ve %36.5±11’ e karşılık %29.1±8.1, p<0.001). Grup 1’ in serum NO ve CD 95 düzeyleri kontrol grubundan daha yüksek bulundu (sırasıyla 73.7±38.9’a karşılık 38.5±17.3 mµ, p<0.01 ve %34.8±9.1’e karşılık %29.1±8.1, p<0.05). Grup 2’ nin serum NO ve CD 95 düzeyleri kontrol grubundan daha yüksek bulundu (sırasıyla 71.0±35.5’ e karşılık 38.5±17.3 mµ, p<0.01 ve %38.1±12.4’ e karşılık %29.1±8.1, p<0.05). Grup 1 ve Grup 2 arasında serum NO ve CD 95 düzeyleri anlamlı farklılık göstermedi (p>0.05). Sonuç: Serum NO ve CD 95 düzeylerinin kronik inaktif hepatit B enfeksiyonu olan çocuklarda ve kronik aktif hepatit B enfeksiyonu olan çocuklarda artış gösterdiği saptanmıştır.

Keywords

Hepatit B virüs kronik hepatit B enfeksiyonu apoptozis CD 95 (FAS) nitrik oksid

Supporting Institution

Destekleyen bir kurum veya kuruluş yoktur.

References

  • The World Health Organization. Hepatitis B. https://www.who.int/news-room/fact-sheets/detail/hepatitis-B. Temmuz 2023’de basıldı. Temmuz 2023’de erişildi.
  • Stinco M, Rubino C, Trapani S, Indolfi G. Treatment of hepatitis B virüs infection in children and adolescents. World J Gastroenterol. 2021;27(36):6053-6063. doi:10.3748/wjg.v27.i36.6053.
  • Indolfi G, Easterbrook P, Dusheiko G, et al. Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol. Hepatol. 2019;4(6): 466–476. doi: 10.1016/S2468-1253(19)30042-1.
  • Türkiye Viral Hepatit Önleme ve Kontrol Programı 2018-2023. https://hsgm .saglik.gov.tr/depo/Yayinlarimiz/Programlar/Turkiye_Viral_Hepatit_Onleme_ve_Kontrol_Programi_2018-2023.pdf;2018.
  • McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985;151(4):599–603. doi: 10.1093/infdis/151.4.599.
  • Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol. 1980;68:251-306. doi: 10.1016/s0074-7696(08)62312-8.
  • Kiraz S, Ertenli I, Oztürk MA, et al. Increased soluble FAS suggest delayed apoptosis in Familial Mediterranean Fever complicated with amyloidozis. J Rheum. 2003;30(2):313-315.
  • Rudin CM, Thompson CB. Apoptosis and Disease: Regulation and Clinical relevance of Programmed Cell Death. Annu. Rev. Med. 1997;48:267-281. doi: 10.1146/annurev.med.48.1.267.
  • Hetts SW. To Die or Not To Die. Jama. 1998; 279(4): 300-307. doi: 10.1001/jama.279.4.300. PMID: 9450715.
  • Rust C, Gores GJ. Apoptosis and Liver disease. Am J Med. 2000;108(7):567-574. doi: 10.1016/s0002-9343(00)00370-3.
  • Andreoli TE. The Apopitotic Syndromes. Am J Med. 1999; 107(5): 488.doi: 10.1016/s0002-9343(99)00258-2.
  • Panossian A, Hambartsumyan M, Panosyan L, et al. Plasma nitric oxide level in Familial Mediterranean Fever and its modulations by Immuno-Guard. Nitric Oxide. 2003; 9(2): 103-110. doi: 10.1016/j.niox.2003.08.005.
  • Braderick A. Clinical manifestations and diagnosis of hepatitis B virüs infection in children and adolescant. UpToDate. Avaible from: http://www uptodate.com. Nisan 2023’de basıldı. Temmuz 2023’de erişildi.
  • Oksuz M, Akkiz H, Isiksal YF, et al. Expression of Fas antigen in liver tissue of patients with chronic hepatitis B and C. Eur J Gastroenterol Hepatol. 2004;16(3): 341-345. doi: 10.1097/00042737-200403000-00015.
  • Mochizuki K, Hayashi N, Hiramatsu N, et al. Fas Antigen Expression in Liver Tissues of Patients With Chronic Hepatitis B. J Hepatol. 1996;24(1):1-7. doi:10.1016/s0168-8278(96)80178-4.
  • Lapinski TW, Kowalczuk O, Prokopowicz D, Chyzewski L. Serum concentration of sFas and sFasL in healty HbsAg carriers, chronic viral hepatitis B and C patients. World J Gastroenterol. 2004;10(24):3650-3653. doi: 10.3748/wjg.v10.i24.3650.
  • Song le H, Binh VQ, Duy DN, et al. Variations in the serum concentrations of soluble Fas and soluble Fas ligand in Vietnamese patients infected with hepatitis B virus. J Med Virol. 2004;73(2):244-249. doi: 10.1002/jmv.20082.
  • Hamazaki K, Gochi A, Matsubara N, Mori M, Orita K. Expression of Fas antigen and Bcl-2 protein in hepatocelluler carsinoma. Acta Med. 1995;49(4):227-230. doi: 10.18926/AMO/30379.
  • Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J. 1994;298:249-258.
  • Guidotti LG, Guilhot S, Chisara FV. Interleukin-2 and alpha/beta interferon downregulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and independent pathways. J Virol.1994;68(3):1265-1270. doi:10.1128/JVI.68.3.1265-1270.1994.
  • Koulentaki M, Notas G, Petinaki E, et al. Nitric oxide and pro-inflammatory cytokines in acute hepatitis B. Eur J Intern Med.2004;15(1):35-38. doi: 10.1016/j.ejim.2003.11.004.
  • Wang K, Han LY, Lu Q, Wang B, Li XH, Wang HM. Nitric oxide and nitric oxide synthase in patients with chronic hepatitis B. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2005; 19(2): 142-145.
  • Liu RH, Jacop JR, Tennant BC, Hotchkiss JH. Nitrite and nitrosamine synthesis by hepatocytes isolated from normal woodchucks (Marmota monax) and woodchucks chronically infected with woodhuck hepatitis virus. Cancer Res. 1992;52(15):4139-4143.
  • Ersoy Y, Bayraktar M, Mızrak B, et al. The level of endothelin-1 and nitric oxide in patients with chronic viral hepatitis B and C and correlation with histopatological grading and staging. Hepatol Res. 2006; 34(2): 111-116. doi: 10.1016/j.hepres.2005.11.005
  • Amaro MJ, Bartolome J, Pardo M, Cotonat T, Lopez A, Carreno V. Decreased nitric oxide production in chronic viral hepatitis B and C. J Med Virol.1997;51(4):326-331. doi: 10.1002/(sici)1096-9071(199704)51:4<326::aid-jmv11>3.0.co;2-g.
There are 25 citations in total.

Details

Primary Language Turkish
Subjects Surgery (Other)
Journal Section Articles
Authors

Aylin Kont Özhan 0000-0003-0486-0422

Mehmet Yavuz Çoşkun 0000-0001-6727-0070

Early Pub Date December 5, 2023
Publication Date December 18, 2023
Submission Date September 18, 2023
Acceptance Date October 17, 2023
Published in Issue Year 2023 Volume: 16 Issue: 3

Cite

APA Kont Özhan, A., & Çoşkun, M. Y. (2023). Çocukluk çağı kronik Hepatit B hastalığının klinik seyir ve tedavisi ile Serum CD 95 (FAS) ve Nitrik Oksid düzeyleri arasındaki ilişkinin belirlenmesi. Mersin Üniversitesi Sağlık Bilimleri Dergisi, 16(3), 495-502.
AMA Kont Özhan A, Çoşkun MY. Çocukluk çağı kronik Hepatit B hastalığının klinik seyir ve tedavisi ile Serum CD 95 (FAS) ve Nitrik Oksid düzeyleri arasındaki ilişkinin belirlenmesi. Mersin Univ Saglık Bilim derg. December 2023;16(3):495-502.
Chicago Kont Özhan, Aylin, and Mehmet Yavuz Çoşkun. “Çocukluk çağı Kronik Hepatit B hastalığının Klinik Seyir Ve Tedavisi Ile Serum CD 95 (FAS) Ve Nitrik Oksid düzeyleri arasındaki ilişkinin Belirlenmesi”. Mersin Üniversitesi Sağlık Bilimleri Dergisi 16, no. 3 (December 2023): 495-502.
EndNote Kont Özhan A, Çoşkun MY (December 1, 2023) Çocukluk çağı kronik Hepatit B hastalığının klinik seyir ve tedavisi ile Serum CD 95 (FAS) ve Nitrik Oksid düzeyleri arasındaki ilişkinin belirlenmesi. Mersin Üniversitesi Sağlık Bilimleri Dergisi 16 3 495–502.
IEEE A. Kont Özhan and M. Y. Çoşkun, “Çocukluk çağı kronik Hepatit B hastalığının klinik seyir ve tedavisi ile Serum CD 95 (FAS) ve Nitrik Oksid düzeyleri arasındaki ilişkinin belirlenmesi”, Mersin Univ Saglık Bilim derg, vol. 16, no. 3, pp. 495–502, 2023.
ISNAD Kont Özhan, Aylin - Çoşkun, Mehmet Yavuz. “Çocukluk çağı Kronik Hepatit B hastalığının Klinik Seyir Ve Tedavisi Ile Serum CD 95 (FAS) Ve Nitrik Oksid düzeyleri arasındaki ilişkinin Belirlenmesi”. Mersin Üniversitesi Sağlık Bilimleri Dergisi 16/3 (December 2023), 495-502.
JAMA Kont Özhan A, Çoşkun MY. Çocukluk çağı kronik Hepatit B hastalığının klinik seyir ve tedavisi ile Serum CD 95 (FAS) ve Nitrik Oksid düzeyleri arasındaki ilişkinin belirlenmesi. Mersin Univ Saglık Bilim derg. 2023;16:495–502.
MLA Kont Özhan, Aylin and Mehmet Yavuz Çoşkun. “Çocukluk çağı Kronik Hepatit B hastalığının Klinik Seyir Ve Tedavisi Ile Serum CD 95 (FAS) Ve Nitrik Oksid düzeyleri arasındaki ilişkinin Belirlenmesi”. Mersin Üniversitesi Sağlık Bilimleri Dergisi, vol. 16, no. 3, 2023, pp. 495-02.
Vancouver Kont Özhan A, Çoşkun MY. Çocukluk çağı kronik Hepatit B hastalığının klinik seyir ve tedavisi ile Serum CD 95 (FAS) ve Nitrik Oksid düzeyleri arasındaki ilişkinin belirlenmesi. Mersin Univ Saglık Bilim derg. 2023;16(3):495-502.
 Download Cover Image

MEU Journal of Health Sciences Assoc was began to the publishing process in 2008 under the supervision of Assoc. Prof. Gönül Aslan, Editor-in-Chief, and affiliated to Mersin University Institute of Health Sciences. In March 2015, Prof. Dr. Caferi Tayyar Şaşmaz undertook the Editor-in Chief position and since then he has been in charge.

Publishing in three issues per year (April - August - December), it is a multisectoral refereed scientific journal. In addition to research articles, scientific articles such as reviews, case reports and letters to the editor are published in the journal. Our journal, which has been published via e-mail since its inception, has been published both online and in print. Following the Participation Agreement signed with TÜBİTAK-ULAKBİM Dergi Park in April 2015, it has started to accept and evaluate online publications.

Mersin University Journal of Health Sciences have been indexed by Turkey Citation Index since November 16, 2011.

Mersin University Journal of Health Sciences have been indexed by ULAKBIM Medical Database from the first issue of 2016.

Mersin University Journal of Health Sciences have been indexed by DOAJ since October 02, 2019.

Article Publishing Charge Policy: Our journal has adopted an open access policy and there is no fee for article application, evaluation, and publication in our journal. All the articles published in our journal can be accessed from the Archive free of charge.

154561545815459

Creative Commons Lisansı
This work is licensed with Attribution-NonCommercial 4.0 International.